Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat plus dapagliflozin versus dapagliflozin in chronic kidney disease with hypertension
2023-506460-14-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 42
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and hypertension (HTN) comparing Baxdrostat plus dapagliflozin with Baxdrostat placebo plus dapagliflozin (2 arms). Primary endpoint: Composite renal and cardiovascular outcome. Planned start May 2025; status: authorised.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on 2023-506460-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506460-14-00.